OBJECTIVE: Red ginseng (RG, Panax ginseng C.A. Meyer) is one of the widely used herbs for treating type 2 diabetes mellitus (DM). However, no systematic review of the effectiveness of RG for type 2 DM is available. This systematic review aimed to evaluate the current evidence for the effectiveness of RG in patients with type 2 DM. METHODS: Electronic searches of 14 electronic databases were conducted without language restrictions. All randomized clinical trials (RCTs) with RG as a treatment for type 2 DM were considered for inclusion. Their methodological quality was assessed using the Cochrane criteria. RESULTS: Four RCTs met our inclusion criteria. Their methodological quality was variable. Three of the RCTs compared the effectiveness of RG with placebo. The meta-analysis of these data failed to favor RG over placebo for fasting plasma glucose (FPG) [n =76, weighted mean difference (WMD): -0.43 mmol/L; 95% confidence interval (CI): -1.16 to 0.30, =0.25] and fasting plasma insulin (FPI) (n =76, WMD: -8.43 pmol/L; 95% CI: -19.54 to 2.68, P =0.14) for 12 weeks of treatment. One RCT compared the effects of RG with no treatment. The results did not suggest favorable effects of RG on FPG, hemoglobin A(1c) (HbA(1c)) or 2-h blood glucose after a meal (PP2h). CONCLUSIONS: The evidence for the effectiveness of RG in controlling glucose in type 2 DM is not convincing. Few included studies with various treatment regimens prohibit definitive conclusions. More rigorous studies are needed to clarify the effects of RG on this condition.
OBJECTIVE: Red ginseng (RG, Panax ginseng C.A. Meyer) is one of the widely used herbs for treating type 2 diabetes mellitus (DM). However, no systematic review of the effectiveness of RG for type 2 DM is available. This systematic review aimed to evaluate the current evidence for the effectiveness of RG in patients with type 2 DM. METHODS: Electronic searches of 14 electronic databases were conducted without language restrictions. All randomized clinical trials (RCTs) with RG as a treatment for type 2 DM were considered for inclusion. Their methodological quality was assessed using the Cochrane criteria. RESULTS: Four RCTs met our inclusion criteria. Their methodological quality was variable. Three of the RCTs compared the effectiveness of RG with placebo. The meta-analysis of these data failed to favor RG over placebo for fasting plasma glucose (FPG) [n =76, weighted mean difference (WMD): -0.43 mmol/L; 95% confidence interval (CI): -1.16 to 0.30, =0.25] and fasting plasma insulin (FPI) (n =76, WMD: -8.43 pmol/L; 95% CI: -19.54 to 2.68, P =0.14) for 12 weeks of treatment. One RCT compared the effects of RG with no treatment. The results did not suggest favorable effects of RG on FPG, hemoglobin A(1c) (HbA(1c)) or 2-h blood glucose after a meal (PP2h). CONCLUSIONS: The evidence for the effectiveness of RG in controlling glucose in type 2 DM is not convincing. Few included studies with various treatment regimens prohibit definitive conclusions. More rigorous studies are needed to clarify the effects of RG on this condition.
Authors: John L Sievenpiper; Mi-Kyung Sung; Marco Di Buono; Kwang Seung-Lee; Ki Yeul Nam; John T Arnason; Lawrence A Leiter; Vladimir Vuksan Journal: J Am Coll Nutr Date: 2006-04 Impact factor: 3.169
Authors: William M Schultz; Elliot N Mahlof; Devinder S Dhindsa; Tina Varghese; Robert E Heinl; Hannah C Cai; Pratik B Sandesara; Danny J Eapen; Laurence S Sperling Journal: Cardiovasc Endocrinol Date: 2017-11-15
Authors: Song Wen-Ting; Cheng Fa-Feng; Xu Li; Lin Cheng-Ren; Liu Jian-Xun Journal: Evid Based Complement Alternat Med Date: 2012-04-24 Impact factor: 2.629
Authors: Esra' Shishtar; John L Sievenpiper; Vladimir Djedovic; Adrian I Cozma; Vanessa Ha; Viranda H Jayalath; David J A Jenkins; Sonia Blanco Meija; Russell J de Souza; Elena Jovanovski; Vladimir Vuksan Journal: PLoS One Date: 2014-09-29 Impact factor: 3.240
Authors: Cicero L T Chang; Yenshou Lin; Arlene P Bartolome; Yi-Ching Chen; Shao-Chih Chiu; Wen-Chin Yang Journal: Evid Based Complement Alternat Med Date: 2013-04-04 Impact factor: 2.629